NASDAQ · Biotechnology · USD

Design Therapeutics, Inc. (DSGN) Stock Analysis

Design Therapeutics, Inc. (DSGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DSGN

$15.14

+$0.11 (+0.73%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DSGN with… →

DSGN Key Statistics

As of Sep 4, 2026

Trading

Open: $14.96
Previous Close: $15.03
Day's Range: 14.96–15.35
52-Week Range: 5.28–17.25
Volume: 256.60K
Beta: 1.66

Valuation

Market Cap: $947.49M
P/E Ratio: unprofitable
EPS (ttm): −1.19

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$69.79M
Profit margin: 0.00%
Shares Outstanding: 62.58M
1-Year Return: +147.79%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 692.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DSGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−37.05%−52.08%−74.17%+132.83%+52.03%+61.41%

2021*20222023202420252026*

Year	Return
2026 (partial year)	+61.41%
2025	+52.03%
2024	+132.83%
2023	−74.17%
2022	−52.08%
2021 (partial year)	−37.05%

As of September 4, 2026.

DSGN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$69.79M	—
2024	$0.00	−$49.59M	—
2023	$0.00	−$66.86M	—
2022	$0.00	−$63.31M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$79.47M	−$69.79M	—
2024	$0.00	—	−$62.38M	−$49.59M	—
2023	$0.00	—	−$78.19M	−$66.86M	—
2022	$0.00	—	−$67.59M	−$63.31M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DSGN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	DSGN	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Design Therapeutics, Inc. (DSGN) is capitalised at $947.49M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 55 employees.

DSGN last closed at $15.14 on September 4, 2026. That is +$0.11 (+0.73%) against the previous close. The 52-week range on file runs from $5.28 to $17.25. The latest close sits 186.74% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $69.79M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.19.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.66. Daily returns over the trailing 5 years annualize to a volatility of 85.31%. The trailing one-year price return is +147.79%. Across 5 years the annualized return works out at −3.08%.

Growth & Income

No dividend is on file for DSGN.

The strongest complete calendar year on file is 2024 at +132.83%; the weakest is 2023 at −74.17%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the price is +61.41%.

Peer Comparison

Design Therapeutics, Inc. (DSGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Design Therapeutics, Inc.	DSGN	$947.49M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Design Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Visit website →